Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers’ understanding of cellular behavior and gene function REDWOOD CITY, Calif. – Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in […]

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels The new offerings solidify leadership in spatial biology and broaden reach to new verticals MARLBOROUGH, Mass. — Akoya Biosciences, a spatial proteomics leader, announced its reagent product roadmap today, featuring new ultrahigh-plex neurobiology […]

Acquisition is the fourth for VION as it continues to expand its portfolio of proprietary products for life science research NASHVILLE, Tenn. — VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, announced its January 2025 acquisition of San Francisco area-based BioAssay Systems, […]

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product PALO ALTO, Calif. — Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and […]

Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation  “New BD,” built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health care Biosciences and Diagnostic Solutions to realize its full market […]

MINNEAPOLIS — Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company’s Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor’s Professor of Bioengineering at the […]

All-in-one kit enables in-house, in vitro profiling of human drug-induced liver injury Rapid access to CN Bio’s FDA-recognized human DILI assay to optimize and de-risk drug candidate selection 24 replicates to support simultaneous assessment of up to eight conditions per kit  Cambridge, UK: CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate […]

Streamlined regulatory documentation accelerates development of next generation therapies SEATTLE — Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its PluriBank™ CG (Clinical Grade) iPSC lines. This comprehensive regulatory submission details […]

Decision Marks a Significant Legal Victory for Parse Biosciences, Reinforcing Commitment to Innovation and Fair Competition SEATTLE — Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) issued Final Written Decisions invalidating […]

ROCKVILLE, Md. — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies. This strategic acquisition strengthens MaxCyte’s ability […]